between crizotinib and chemotherapy among responders, owing to the higher objective response rate in the crizotinib arm, it would undermine the treatment benefit with respect to DOR. A caveat for our proposal is that mean DOR depends on a specific time window that can be preselected based on clinical consideration. Empirically one may choose the largest possible time window beyond which a small proportion of patients (eg, 2%) remain at risk for P/D. Like other procedures such as hazard ratio estimation, this time window constraint may not be avoidable without a parametric model for extrapolation. Lastly, it can be quite informative to examine the temporal treatment effect profile by choosing several time windows to estimate restricted mean differences in DOR. Role of the Funder/Sponsor: The National Institutes of Health had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
1. US Food and Drug Administration. Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics. Washington, DC, US Food and Drug Administration. 2007 May:1-9. https://www.fda.gov/downloads /Drugs/Guidances/ucm071590.pdf. Accessed January 8, 2018. Methods | The data source is the 2015 US National Health Interview Survey (NHIS), a cross-sectional in-person interview gathering self-reported health data for the US population. The study did not meet regulatory definition of a "human subject" study because the data are publically available. Therefore, neither certification of exemption from University of California Los Angeles institutional review board approval was not required. The outcome of interest was receipt of genetic testing for cancer risk. Affirmative responders were asked 4 subsequent questions that were not mutually exclusive-if their test was for breast cancer, ovarian cancer, colon or rectal cancer, or other cancer. Answers did not have to be concordant with personal and family history.
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Sociodemographic factors of individuals obtaining genetic testing were compared with the national sample, including gender, US Census region, race/ethnicity, insurance, citizenship, and education.
To assess the gender disparity in testing, we stratified by type of testing and cancer status. To evaluate potential underrecognition of family medical history leading to lower testing rates, we compared select family medical histories between unaffected men and women.
All estimates were adjusted for complex survey weights and used Taylor series standard errors. Bivariate comparisons were made using adjusted Wald tests and rate ratios (RRs) were generated via Poisson regression.
Results | In the 2015 NHIS, 378 adults (≥18 years) reported a history of genetic testing for cancer, representing 2 498 842 people. Sociodemographic differences in the testing subsample included a lower proportion of Hispanics (10% vs 16%; P = .002), the uninsured (2% vs 10%; P<.001), noncitizens (4% vs 8%; P < .001), and those with less education (high school or General Educational Development (GED) diploma; 30% vs 44%; P < .001). Almost 3 times as many women received testing as men (73% vs 27%; P < .001). This disparity persisted for unaffected men, testing at half the rate of unaffected women (RR, 0.51; 95% CI, 0.36-0.73) ( Table 1) .
Three-quarters of genetic testing was for breast/ovarian cancer, 24% for colorectal cancer, and 22% for other cancers.
Among the unaffected, men underwent testing for breast/ ovarian cancer at one-tenth the rate of women (RR, 0.10; 95% CI, 0.05-0.23). There was no gender disparity for colorectal or other cancer testing ( Table 2) .
There were no differences in reported family history between unaffected men and women (number of first-degree female relatives with breast cancer, breast cancer at ≤50 years, or ovarian cancer).
Discussion | Cancer genetic testing seems to reach a broad geographic and sociodemographic population in this national survey. However, there remain underrepresented groups, including Hispanics, the uninsured, noncitizens, and those with less tested men were prostate (n = 5), colon (n = 4), and nonmelanoma skin (n = 4). i Top 3 reported cancers among tested women were breast (n = 80), ovarian (n = 14), and uterine (n = 9). To our knowledge, no randomized clinical trials (RCTs) have been conducted regarding patients' perception of their health care professional who use an examination room computer (ERC) during clinic visits. Our primary objective was to compare patients' perception of physicians' compassion; secondary objectives were to compare patients' perception of physicians' communication skills and professionalism and patients' overall physician preference after watching 2 standardized scripted-video vignettes of physicians: one portraying a face-to-face (F2F) clinic visit and the other one portraying a physician using an ERC.
Methods | MD Anderson Cancer Center's institutional review board approved this RCT (clinicaltrials.gov number NCT02957565). See trial protocol in the Supplement. Patients were recruited from the palliative care (PC) clinic if they spoke English, were 18 years or older, and had advanced cancer (locally advanced, recurrent, or metastatic). All patients provided written informed consent forms and were offered a $25 gift card. Ninety percent of patients seen in the PC clinic have advanced cancer with a median survival of 8 months' survival, and all patients are being treated by a multidisciplinary PC team.
Scripted-video vignettes were used to deliver the interventions as recommended by Hillen et al 1 and van Vliet et al 2 in collaboration with the creative services department at MD Anderson. Video production consisted of 5 phases: determining the clinical situation, developing a script, hiring professional actors and recording videos in an outpatient setting, obtaining expert review of the videos, and performing final editing. In F2F videos, the physician used a notepad to record notes, whereas in the ERC videos, the physician used a stationary computer to access information and type notes while minimizing disruption in eye contact. An identical script was used for both scenarios. Five faculty members who were blinded to the study hypothesis performed an independent review of the recordings to ensure that physicians' expressions and emotional quotients were matched. A randomized controlled crossover design was used to allocate 120 patients into the F2F or ERC arm. Random allocation sequence was generated by Clinical Oncology Research Database (CORe) software. All patients watched both videos (Figure) . The research coordinator (M.E.) enrolled and assigned patients to the interventions. The research coordinator (M.E.) and principal investigator (A.H.) were blinded to the sequence in which patients watched the videos. Actors and patients were blinded to the specific hypothesis of the study.
After viewing each video, the patients completed validated questionnaires rating physicians' compassion 3, 4 (0 = best, 50 = worst), communication skills 5 (14 = poor, 70 = excellent), and professionalism 6 (4 = poor, 20 = very good) and were asked to rate overall physician preference. In each group (F2F and ERC), 60 patients had 80% power to detect an effect size of 0.516 on the primary outcome of physicians' compassion after the first video, using a 2-sample t test with a α level of 0.05. Standard descriptive statistics were used when applicable. All tests were 2-sided. P ≤ .50 was considered statistically significant. All computations were carried out using SAS statistical software (version 9.3; SAS Institute Inc). 
